{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:13:01Z","timestamp":1788988381457,"version":"build-2803163510"},"reference-count":124,"publisher":"Massachusetts Medical Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.1056\/nejmra2605253","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:00:16Z","timestamp":1788987616000},"page":"992-1008","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Decisions in Multiple Myeloma"],"prefix":"10.1056","volume":"395","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":false,"given":"Tarek H.","family":"Mouhieddine","sequence":"first","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Dana\u2013Farber Cancer Institute, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Dana\u2013Farber Cancer Institute, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00913-y"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-25-0107"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01041-x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240966"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018537"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01733"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00289"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.262360"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Perrot A Lauwers-Cances V Cazaubiel T et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood 2020;136:Suppl 1:39-39. abstract (https:\/\/ashpublications.org\/blood\/article\/136\/Supplement%201\/39\/470028\/Early-Versus-Late-Autologous-Stem-Cell-Transplant).10.1182\/blood-2020-13453810.1182\/blood-2020-134538","DOI":"10.1182\/blood-2020-134538"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026230"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017094"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009138"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00282-1"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02266"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0611"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Landgren CO Ye JC Hillengass J et al. Randomized multi-center study of carfilzomib lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): the ADVANCE clinical trial. J Clin Oncol 2025;43:Suppl:7503-7503. abstract (https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.7503).","DOI":"10.1200\/JCO.2025.43.16_suppl.7503"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04282-0"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02505-2"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00535-0"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00693-3"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00738-0"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025746"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3160"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2600157"},{"key":"e_1_3_3_42_2","unstructured":"van de Donk NWCJ Silzle T \u0160pi\u010dka I et al. Teclistamab (tec) +\/\u2212 lenalidomide (len) versus len alone as maintenance therapy post-transplant in newly diagnosed multiple myeloma (NDMM): updated safety run-in (SRI) results from EMN30\/MajesTEC-4. Presented at the EHA2026 Congress Stockholm June 11\u201314 2026 (https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4206751\/niels.w.c.j.van.de.donk.teclistamab.28tec29.2B.-.lenalidomide.28len29.versus.len.html)."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30147-8"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00381-1"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01494-y"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00653-9"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_3_51_2","doi-asserted-by":"crossref","unstructured":"Parekh S Li K Van De Donk NWCJ et al. Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study. Blood 2025;146:Suppl 1:92-92. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/92\/549696\/Earlier-use-of-ciltacabtagene-autoleucel-cilta-cel).","DOI":"10.1182\/blood-2025-92"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01465-x"},{"key":"e_1_3_3_53_2","doi-asserted-by":"crossref","unstructured":"Rejeski K Hansen DK Cordas Dos Santos DM et al. Pre-apheresis prediction of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. Blood 2024;144:Suppl 1:895-895. abstract (https:\/\/ashpublications.org\/blood\/article\/144\/Supplement%201\/895\/530847\/Pre-Apheresis-Prediction-of-Toxicity-and-Response).","DOI":"10.1182\/blood-2024-208376"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00117-6"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00929-0"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02482-6"},{"key":"e_1_3_3_57_2","doi-asserted-by":"crossref","unstructured":"Duvalyan E Song J Shenoy S et al. How long is long enough? Outcomes with finite-duration bispecific antibody therapy in multiple myeloma. J Clin Oncol 2026;44:Suppl:7538-7538. abstract (https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2026.44.16_suppl.7538).","DOI":"10.1200\/JCO.2026.44.16_suppl.7538"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016911"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04522-3"},{"key":"e_1_3_3_64_2","doi-asserted-by":"crossref","unstructured":"Harrison S Hasselbalch Riley C Mian H et al. Tumor clearance T-cell fitness and minimal residual disease (MRD) outcomes in patients with relapsed\/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: biomarker analyses from CAMMA 1 Arm B. Blood 2025;146:Suppl 1:252-252. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/252\/548763\/Tumor-clearance-T-cell-fitness-and-minimal).","DOI":"10.1182\/blood-2025-252"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002524"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029360"},{"key":"e_1_3_3_68_2","doi-asserted-by":"crossref","unstructured":"Quach H Perrot A Matous J et al. Talquetamab a GPRC5D\u00d7CD3 bispecific antibody in combination with pomalidomide in patients with relapsed\/refractory multiple myeloma: Updated safety and efficacy results from the phase 1b MonumenTAL-2 study. Blood 2025;146:Suppl 1:2282-2282. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/2282\/553284\/Talquetamab-a-GPRC5D-CD3-bispecific-antibody-in).","DOI":"10.1182\/blood-2025-2282"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2604657"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2603870"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406536"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514752"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30049-7"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_3_80_2","doi-asserted-by":"crossref","unstructured":"Manier S Lambert J Macro M et al. A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial cohort A. Blood 2025;146:Suppl 1:367-367. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/367\/553337\/A-phase-2-Study-of-teclistamab-in-combination-with).","DOI":"10.1182\/blood-2025-367"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04471-x"},{"key":"e_1_3_3_82_2","doi-asserted-by":"crossref","unstructured":"Sureda Balar\u00ed A Khan A Oriol A et al. Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial. Blood 2025;146:Suppl 1:5810-5810. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/5810\/552478\/Iberdomide-plus-daratumumab-and-dexamethasone).","DOI":"10.1182\/blood-2025-5810"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00290-3"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2501920"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303194"},{"key":"e_1_3_3_86_2","doi-asserted-by":"crossref","unstructured":"Oriol A Richardson P Raab M et al. Efficacy of mezigdomide plus dexamethasone and bortezomib or carfilzomib in patients with relapsed\/refractory multiple myeloma by line of therapy: results from the phase 1\/2 CC-92480-MM-002 trial. Clin Lymphoma Myeloma Leuk 2025;25:Suppl 2:S36-S37. abstract (https:\/\/www.clinical-lymphoma-myeloma-leukemia.com\/article\/S2152-2650(25)03458-5\/abstract).","DOI":"10.1016\/S2152-2650(25)03458-5"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)01088-3"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00298-4"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-251"},{"key":"e_1_3_3_90_2","unstructured":"FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma. Press release of the Food and Drug Administration Silver Spring MD August 13 2026 (https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone)."},{"key":"e_1_3_3_91_2","doi-asserted-by":"crossref","unstructured":"Dhakal B Yee A Richardson P et al. Updated results of a phase 1 first-in-human study of cemsidomide (CFT7455) a novel MonoDAC degrader with dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk 2025;25:Suppl:S35-S35. abstract (https:\/\/www.clinical-lymphoma-myeloma-leukemia.com\/article\/S2152-2650(25)03456-1\/abstract).","DOI":"10.1016\/S2152-2650(25)03456-1"},{"key":"e_1_3_3_92_2","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ Vega G Perrot A et al. First-in-human study of JNJ-79635322 (JNJ-5322) a novel next-generation trispecific antibody (TsAb) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results. J Clin Oncol 2025;43:Suppl:7505-7505. abstract (https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.7505).","DOI":"10.1200\/JCO.2025.43.16_suppl.7505"},{"key":"e_1_3_3_93_2","doi-asserted-by":"crossref","unstructured":"Quach H Augustson B Levitz D et al. TRIgnite-1 study phase 1 first-in-human study of ISB 2001:a BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed\/refractory multiple myeloma (RRMM) \u2014 dose escalation (DE) results. Clin Lymphoma Myeloma Leuk 2025;25:Suppl 2:S23-S24. abstract (https:\/\/www.clinical-lymphoma-myeloma-leukemia.com\/article\/S2152-2650(25)03439-1\/abstract).","DOI":"10.1016\/S2152-2650(25)03439-1"},{"key":"e_1_3_3_94_2","doi-asserted-by":"crossref","unstructured":"Li J Li Z Li C et al. Initial results of the first-in-human phase 1 study of IBI3003 a novel trispecific antibody targeting GPRC5D BCMA and CD3 in patients with relapsed or refractory multiple myeloma. Blood 2025;146:Suppl 1:702-702. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/702\/554956\/Initial-Results-of-the-first-in-human-Phase-1).","DOI":"10.1182\/blood-2025-702"},{"key":"e_1_3_3_95_2","doi-asserted-by":"crossref","unstructured":"Patel K Dhakal B Kaur G et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: updated results from iMMagine\u20131. Blood 2025;146:Suppl 1:256-256. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/256\/548759\/Phase-2-registrational-study-of-anitocabtagene).10.1182\/blood-2025-25610.1182\/blood-2025-256","DOI":"10.1182\/blood-2025-256"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030750"},{"key":"e_1_3_3_97_2","doi-asserted-by":"crossref","unstructured":"Richard S Gaballa M Gregory T et al. Safety and efficacy of AZD0120 a BCMA\/CD19 dual-targeting CAR T-cell therapy in relapsed\/refractory multiple myeloma: preliminary results from the DURGA-1 phase 1b\/2 study. Blood 2025;146:Suppl 1:269-269. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/269\/552695\/Safety-and-efficacy-of-AZD0120-a-BCMA-CD19-dual).","DOI":"10.1182\/blood-2025-269"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-270"},{"key":"e_1_3_3_99_2","doi-asserted-by":"crossref","unstructured":"Hu Y Zhang M Zhang Y et al. OL-101 a BCMA\/GPRC5D dual-targeting autologous CAR-T for relapsed\/refractory multiple myeloma (R\/R MM): results from a phase I study. EHA 2026. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/2387\/549094\/OL-101-a-BCMA-GPRC5D-dual-targeting-autologous-CAR).","DOI":"10.1182\/blood-2025-2387"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00176-5"},{"key":"e_1_3_3_101_2","unstructured":"Harrington K Jones JC Oh Y et al. Development of BMS-986453 a dual-targeting BCMA\u00d7GPRC5D chimeric antigen receptor (CAR) for the treatment of multiple myeloma. Presented at EHA2026 Congress Stockholm June 11\u201314 2026. abstract (https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4206742\/doris.hansen.development.of.bms-986453.a.dual-targeting.bcmagprc5d.chimeric.html)."},{"key":"e_1_3_3_102_2","unstructured":"Dhakal B Rossi A Clark W et al. CB-011 an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking for patients with relapsed\/refractory multiple myeloma (CAMMOUFLAGE phase 1 trial). Presented at the EHA2026 Congress Stockholm June 11\u201314 2026 (https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4206755\/binod.dhakal.cb-011.an.allogeneic.anti-bcma.car-t.cell.therapy.with.immune.html)."},{"key":"e_1_3_3_103_2","doi-asserted-by":"crossref","unstructured":"Dholaria B Shune LO Kocoglu MH et al. A phase 1 study of P-BCMA-ALLO1 a non-viral allogeneic BCMA directed CAR-T in relapsed\/refractory multiple myeloma (RRMM): results from optimized lymphodepletion cohort. Blood 2024;144:Suppl 1:4828-4828. abstract (https:\/\/ashpublications.org\/blood\/article\/144\/Supplement%201\/4828\/533291\/A-Phase-1-Study-of-P-BCMA-ALLO1-a-Non-Viral).","DOI":"10.1182\/blood-2024-207459"},{"key":"e_1_3_3_104_2","doi-asserted-by":"crossref","unstructured":"Harrison S Ho PJ Lim S-L et al. Minimal residual disease (MRD)-negative outcomes following a novel in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR the first-in-human phase 1 study of KLN-1010. Blood 2025;146:Suppl 2:LBA-1-LBA-1. abstract.","DOI":"10.1182\/blood-2025-LBA-1"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01030-X"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04244-6"},{"key":"e_1_3_3_107_2","doi-asserted-by":"crossref","unstructured":"Garnaas M Cowens K Zhang Z et al. Preclinical proof-of-concept of an mRNA-based T cell engager targeting BCMA FcRH5 and GPRC5D for the treatment of multiple myeloma. Blood 2024;144:Suppl 1:4163-4163. abstract (https:\/\/ashpublications.org\/blood\/article\/144\/Supplement%201\/4163\/533882\/Preclinical-Proof-of-Concept-of-an-mRNA-Based-T).","DOI":"10.1182\/blood-2024-207674"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02339-4"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028597"},{"key":"e_1_3_3_110_2","doi-asserted-by":"crossref","unstructured":"Maroto Martin E He M Khan R et al. Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies. Blood 2025;146:Suppl 1:2332-2332. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/2332\/554457\/Development-of-novel-MZB1-directed-HLA-dependent).","DOI":"10.1182\/blood-2025-2332"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30124-3"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01740"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409029"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.07.030"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.10.017"},{"key":"e_1_3_3_116_2","doi-asserted-by":"crossref","unstructured":"Nadeem O Magidson S Redd RA et al. Phase II trial of daratumumab bortezomib lenalidomide and dexamethasone in high-risk smoldering multiple myeloma. Blood 2024;144:Suppl 1:3360. abstract (https:\/\/ashpublications.org\/blood\/article\/144\/Supplement%201\/3360\/533753\/Phase-II-Trial-of-Daratumumab-Bortezomib).","DOI":"10.1182\/blood-2024-202653"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55308-5"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02771"},{"key":"e_1_3_3_119_2","unstructured":"Kumar S Laplant B Badros A et al. Aggressive smoldering curative approach evaluating novel therapies (ASCENT): a phase 2 trial of induction consolidation and maintenance in high-risk smoldering multiple myeloma. Presented at the EHA2026 Congress Stockholm June 11\u201314 2026 (https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4206761\/shaji.kumar.aggressive.smoldering.curative.approach.evaluating.novel.therapies.html)."},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3971"},{"key":"e_1_3_3_121_2","unstructured":"Nadeem O Cordas Dos Santos D Magidson S et al. Teclistamab improves depth of response and PFS versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: results from the phase 2 ImmunoPRISM trial. Presented at the EHA2026 Congress Stockholm June 11\u201314 2026 (https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4214975\/omar.nadeem.teclistamab.improves.depth.of.response.and.pfs.versus.html)."},{"key":"e_1_3_3_122_2","doi-asserted-by":"crossref","unstructured":"Touzeau C Schjesvold F Cerchione C et al. Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: first results from the phase 2 ERASMM (EMN34) study. J Clin Oncol 2026;44:Suppl:7500-7500. abstract (https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2026.44.16_suppl.7500).","DOI":"10.1200\/JCO.2026.44.16_suppl.7500"},{"key":"e_1_3_3_123_2","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Otero P Lleonart JJB Clavero ME et al. Safety and efficacy of linvoseltamab (LINVO) in patients (pts) with high-risk smoldering multiple myeloma (HR-SMM): first results from the phase 2 LINKER-SMM1 trial. Clin Lymphoma Myeloma Leuk 2025;25:Suppl 2:S366-S367. abstract (https:\/\/www.clinical-lymphoma-myeloma-leukemia.com\/article\/S2152-2650(25)04011-X\/abstract).","DOI":"10.1016\/S2152-2650(25)04011-X"},{"key":"e_1_3_3_124_2","doi-asserted-by":"crossref","unstructured":"Landgren CO Diamond B Pandey A et al. A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: first pre-planned analysis (the REVIVE study). Blood 2025;146:Suppl 1:5775-5775. abstract (https:\/\/ashpublications.org\/blood\/article\/146\/Supplement%201\/5775\/553700\/A-phase-2-trial-of-teclistamab-plus-daratumumab).","DOI":"10.1182\/blood-2025-5775"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04365-y"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMra2605253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:00:24Z","timestamp":1788987624000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMra2605253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":124,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,10]]}},"alternative-id":["10.1056\/NEJMra2605253"],"URL":"https:\/\/doi.org\/10.1056\/nejmra2605253","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}